AstraZeneca PLC (LSE:AZN) is set to pay out US$775mln to settle a patent dispute between its recently acquired rare diseases business Alexion and the Chugai Pharmaceutical Company. The litigation relates to a drug called Ultomiris, used to treat paroxysmal nocturnal hemoglobinuria and atypical haemolytic uraemic syndro
Full Story >>
Vote
+39